Role of the p38 MAPK pathway in cisplatin-based therapy

Oncogene

Volumn 22, Issue 26, 2003, Pages 3998-4006

  Losa, Javier Hernández ^a   Cobo, Carlos Parada ^a   Viniegra, Juan Guinea ^a   Sánchez Arevalo Lobo, Victor Javier ^a   Ramón y Cajal, Santiago ^a   Sánchez Prieto, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Cisplatin; p38 MAPK; p38 MAPK ERK6; p38 MAPK SAPK4; Phosphorylation resistance

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ANTIBODY; CISPLATIN; DOXORUBICIN; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PLATINUM DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSPLATIN;

ARTICLE; CANCER THERAPY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME KINETICS; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL LINE; CELL SURVIVAL; CISPLATIN; COS CELLS; CROSS-LINKING REAGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; HELA CELLS; HUMANS; IMIDAZOLES; KINETICS; MAP KINASE KINASE 3; MAP KINASE KINASE 6; MITOGEN-ACTIVATED PROTEIN KINASE 12; MITOGEN-ACTIVATED PROTEIN KINASE 13; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; PHOSPHORYLATION; PLASMIDS; PLATINUM COMPOUNDS; PRECIPITIN TESTS; PROTEIN ISOFORMS; PROTEIN-TYROSINE KINASES; PYRIDINES; SIGNAL TRANSDUCTION; THIAZOLES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0038339253     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206608     Document Type: Article

References (54)

1. Alonso G, Ambrosino C, Jones M and Nebreda AR. (2000). J. Biol. Chem., 275, 40641-40648.
2. Asselin E, Mills GB and Tsang BK. (2001). Cancer Res., 61, 1862-1868.
3. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y and Seger R. (2001). Oncogene, 20, 147-155.
4. Blagosklonny MV and Fojo T. (1999). Int. J. Cancer., 83, 151-156.
5. Boudvillain M, Dalbies R, Aussourd C and Leng M. (1995). Nucleic Acids Res., 23, 2381-2388.
6. Brognard J, Clark AS, Ni Y and Dennis PA. (2001). Cancer Res., 61, 3986-3997.
7. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E and Fornace Jr AJ. (1999). EMBO J., 18, 6845-6854.
8. Chen Z, Seimiya H, Naito M, Mashima T, Kizaki A, Dan S, Imaizumi M, Ichijo H, Miyazono K and Tsuruo T. (1999). Oncogene, 18, 173-180.
9. Chiariello M, Marinissen MJ and Gutkind JS. (2000). Mol. Cell Biol., 20, 1747-1758.
10. Cong F and Goff SP. (1999). Proc. Natl. Acad. Sci. USA, 96, 13819-13824.
11. Cuenda A, Alonso G, Morrice N, Jones M, Meier R, Cohen P and Nebreda AR. (1996). EMBO J., 15, 4156-4164.
12. Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC and Persons DL. (2000). Mol. Carcinog., 29, 219-228.
13. Cummings J and Smyth JF. (1993). Ann. Oncol., 4, 533-543.
14. Davies P, Reddy H, Caviano M and Cohen P. (2000). Biochem. J., 351, 95-105.
15. Galan A, Garcia-Bermejo ML, Troyano A, Vilaboa NE, de Bias E, Kazanietz MG and Aller P. (2000). J. Biol. Chem., 275, 11418-11424.
16. Gonzalez VM, Fuertes MA, Alonso C and Perez JM. (2001). Mol. Pharmacol., 59, 657-663.
17. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T and Murata Y. (2000). Cancer Res., 60, 5988-5994.
18. Hortobagyi GN. (1999). Semin. Oncol., 26, 32-36.
19. Jiang Y, Gram H, Zhao M, New L Gu J, Feng L, Di Padova F, Ulevitch RJ and Han J. (1997). J. Biol. Chem., 272, 30122-30128.
20. Kasparkova J and Brabec V. (1995). Biochemistry, 34, 12379-12387.
21. Kasparkova J, Pospisilova S and Brabec V. (2001). J. Biol. Chem., 276, 16064-16069.
22. Khanna KK and Jackson SP. (2001). Nat. Genet., 27, 247-254.
23. Kharbanda S, Pandey P, Ren R, Mayer B, Zon L and Kufe D. (1995). J. Biol. Chem., 270, 30278-30281.
24. Kharbanda S, Yuan ZM, Weichselbaum R and Kufe D. (1998). Oncogene, 17, 3309-3318.
25. Kyriakis JM and Avruch J. (2001). Physiol. Rev., 81, 807-869.
26. Lakin ND and Jackson SP. (1999). Oncogene. 18, 7644-7655.
27. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Stickler JE, Mclaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL and Young PR. (1994). Nature, 372, 739-746.
28. Lippert B. (1996). Met. Ions. Biol. Syst., 33, 105-141.
29. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC and Testa JR. (2000). Cancer Res., 60, 5390-5394.
30. Nebreda AR and Porras A. (2000). Trends Biochem. Sci., 25, 257-260.
31. Nomura M, Kaji A, Ma WY, Zhong S, Liu G, Bowden GT, Miyamoto Ki K and Dong Z. (2001). J. Biol. Chem., 11, 11.
32. Okano J and Rustgi AK. (2001). J. Biol. Chem., 276, 19555-19564.
33. Pandey P, Raingeaud J, Kaneki M, Weichselbaum R, Davis RJ, Kufe D and Kharbanda S. (1996). J. Biol. Chem., 271, 23775-23779.
34. Patel V, Jakus J, Harris CM, Ensley J, Robbins K and Yeudall WA. (1997). Int. J. Cancer., 73, 551-555.
35. Patel V, Senderowick A, Pinto D, Igishi T, Raffeld N, Quintanilla-Martinez L, Ensley J, Sausville E and Gutkind JS. (1998). J. Clin. Invest., 102, 1674-1681.
36. Pillaire MJ, Nebreda AR and Darbon JM. (2000). Biochem. Biophys. Res. Commun., 278, 724-728.
37. Rane MJ, Coxon PY, Powell DW, Webster R, Klein JB, Pierce W, Ping P and McLeish KR. (2001). J. Biol. Chem., 276, 3517-3523.
38. Sanchez-Perez I, Martinez-Gomariz M, Williams D, Keyse SM and Perona R. (2000). Oncogene, 19, 5142-5152.
39. Sanchez-Perez I, Murguia JR and Perona R. (1998). Oncogene, 16, 533-540.
40. Sanchez-Perez I and Perona R. (1999). FEBS Lett., 453, 151-158.
41. Sanchez-Prieto R, Rojas JM, Taya Y and Gutkind JS. (2000). Cancer Res., 60, 2464-2472.
42. Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja JM and Gutkind JS. (2002). Oncogene, 21, 974-979.
43. She QB, Chen N and Dong Z. (2000). J. Biol. Chem., 275, 20444-20449.
44. Smith GC and Jackson SP. (1999). Genes Dev., 13, 916-934.
45. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA and Gutkind JS. (2000). Cancer Res., 60, 4873-4880.
46. Trimmer EE and Essigmann JM. (1999). Essays Biochem., 34, 191-211.
47. Verheij M, Ruiter GA, Zerp SF, van Blitterswijk WJ, Fuks Z, Haimovitz-Friedman A and Bartelink H. (1998). Radiother Oncol., 47, 225-232.
48. Viniegra JG, Losa JH, Sanchez-Arevalo VJ, Cobo CP, Soria VM, SR YC and Sanchez-Prieto R. (2002). Oncogene, 21, 7131-7136.
49. Wang X, Martindale JL and Holbrook NJ. (2000a). J. Biol. Chem., 275, 39435-39443.
50. Wang X, McGowan CH, Zhao M, He L Downey JS, Fearns C, Wang Y, Huang S and Han J. (2000b). Mol. Cell. Biol., 20, 4543-4552.
51. Watanabe H, de Caestecker MP and Yamada Y. (2001). J. Biol. Chem., 276, 14466-14473.
52. Yu ZP, Matsuoka M, Wispriyono B, Iryo Y and Igisu H. (2000). Toxicol. Appl. Pharmacol., 168, 200-207.
53. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnel PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL and Lee JC. (1997). J. Biol. Chem., 272, 12116-12121.
54. Zlatanova J, Yaneva J and Leuba SH. (1998). FASEB J., 12, 791-799.